Awaiting development: Guidance and quality standards

Showing 276 to 283 of 283

Guidance and quality standards awaiting development
Title	Type
Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672]	Technology appraisal guidance
Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]	Technology appraisal guidance
Zavegepant for treating acute migraine [TSID11998]	Technology appraisal guidance
Zilugisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]	Technology appraisal guidance
Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]	Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]	Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040]	Technology appraisal guidance
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]	Technology appraisal guidance